THE HISTOPATHOLOGICAL CHARACTERISTICS AND EXPRESSION STATUS OF MLH1, MSH2, MSH6, PMS2 PROTEINS IN COLORECTAL ADENOCARCINOMA AT CAN THO ONCOLOGY HOSPITAL IN 2019-2020
Main Article Content
Abstract
Background: In colorectal adenocarcinoma, it is critical to determine the expressions of mismatch repair proteins that are strongly associated with the prognosis and the response prediction to 5-FU chemotherapy. Objectives: 1) to determine the rates of the histopathological characteristic of colorectal adenocarcinoma at Can Tho Oncology Hospital from 2019 to 2020; 2) to determine the percentage of loss expression of MLH1, MSH2, MSH6, PMS2 proteins, as well as their involvement with the histopathological characteristic of colorectal adenocarcinoma at Can Tho Oncology Hospital from 2019 to 2020. Materials and Methods: A cross-sectional descriptive study was conducted on 131 patients diagnosed as colorectal adenocarcinoma via HE staining, included from January 2019 to July 2020. The Immunohistochemistry technique was carried out of the 5µm slices of patient's tumor tissue to determine the MLH1, MSH2, MSH6, PMS2 proteins expressions at the Anapathology department – Can Tho Oncology Hospital. Results: On 131 colorectal adenocarcinoma patients, the adenocarcinoma type accounted almost for 90.1%, and mucous or ring cell and micropapillary adenocarcinoma type accounted for 9.9 %. The low-grade carcinoma and high-grade carcinoma were respectively 92.4% and 7.6%. The rate of dMMR was 36.6% and the rates of loss expression of each protein types by immunohistochemistry stained technique were 26% for MLH1, 16.8% for MSH2, 17.6% for MSH6 and 22.1% for PMS2, respectively. There was not a significant correlation between the loss of proteins expression with pathohistological type, and pathohistological grade. Conclusion: The adenocarcinoma was the major type of colorectal adenocarcinoma (90.1%). Almost tumors have had histological low-grade (92.4%). The rate of loss of MLH1 protein was highest (26%), whereas the rate of loss of MSH2 protein was lowest (16.8%). The total rate of dMMR was 36.6%. There was no significant correlation between the loss of MSH2, MSH6, PMS2 proteins expression with histopathological type and histopathological grade.
Keywords
mismatch repair, microsatellite instability, immunohistochemistry, colorectal cancer
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
2. Bùi Ánh Tuyết (2017). Nghiên cứu đặc điểm Lâm sàng và tình trạng đột biến gen Kras trong ung thư đại-trực tràng tại Bệnh viện K. Luận án tiến sĩ. Trường Đại học Y Hà Nội.
3. Amira A. T., Mouna T., et al (2014). Immunohistochemical expression pattern of MMR protein can specifically identify patients with colorectal cancer microsatellite instability. Tumor Biology, 35(7), 6283–6291.
4. Bartley A.N., Hamilton S.R., et al (2014). Template for reporting results of biomarker testing of specimens from patients with carcinoma of the colon and rectum. Arch Pathol Lab Med, 138 (2), 166–70.
5. Copija A., Waniczek D., et al (2017). Clinical Significance and Prognostic Relevance of Microsatellite Instability in Sporadic Colorectal Cancer Patients. Int J Mol Sci. 18 (1), 107.
6. Grant M., Haydon A., et al (2018). Immunohistochemistry testing for mismatch repair deficiency in Stage 2 colon cancer: A cohort study of two cancer centres. International journal of surgery (London, E ngland), 51, 71–75.
7. Kawakami H., Zaanan A., Sinicrope F.A. (2015). Implications of mismatch repairdeficient status on management of early stage colorectal cancer. J Gastrointest Oncol, 6 (6), 676-84.
8. Nagtegaal I. D., Arends M. J., Odze R.D. (2019). WHO Classilication of Tumours: Digestive System, 5th edition, volume 1. Tumours of the colon and rectum, pp. 157-191
9. Srdjan M., Jadranka A., Ivan D., et al (2016). Microsatellite instability & survival in patients with stage II/III colorectal carcinoma. Indian J Med Res, 143 (Supplement), S104-S111.